Clinical Trial
program
target
indication
moa
development stage
CT3001
TMER1-i
Small molecule
GPR35
a.k.a.
Kynurenic Acid Receptor
IO, first-in-class
GPR35+ IDO1+ Tumors:
Colon, Pdac, Gastric, NSCLC
Hippo-YAP regulator
Block IDO-mediated tumor immune escape
Block tumor growth
CT3001 Study Overview | Brief Summary
This is an FIH, multicenter, open-label, dose escalation and dose expansion study of CT3001, which will be conducted in 2 phases: Phase 1 and Phase 2a. Phase 1 will be a standard 3+3 dose escalation and dose finding study in patients with advanced solid tumors for whom there is no available therapy (or patients are not candidates for such therapy) for the assessment of DLTs at up to 6 dose levels of CT3001. Phase 2a is a dose expansion study to evaluate the preliminary efficacy of CT3001 in patients with advanced CRC or PDAC.